Anthocyanins / BioEnh Cancer Research Results

ACNs, Anthocyanins: Click to Expand ⟱
Features:

Anthocyanins — Anthocyanins (ACNs) are a structurally diverse class of water-soluble flavonoid pigments (glycosylated anthocyanidins) abundant in berries, purple/red grapes, cherries, red cabbage, and other deeply colored plants. They function as pleiotropic redox- and inflammation-modulating polyphenols with context-dependent signaling effects that can shift from antioxidant/anti-inflammatory tone at nutritionally relevant exposures to stress-signaling/pro-apoptotic effects in tumor models at higher concentrations. Classification: dietary polyphenols (flavonoids; anthocyanidin O-glycosides). Standard abbreviations: ACNs; often specified as C3G (cyanidin-3-O-glucoside) or as “total anthocyanins.” A key translation nuance is that circulating parent ACNs are typically low and transient, while phase-II conjugates and gut microbiota–derived phenolic acids (e.g., protocatechuic acid from cyanidin glycosides) plausibly mediate a meaningful fraction of systemic biology.

Primary mechanisms (ranked):

  1. Inflammation attenuation via NF-κB pathway suppression and downstream cytokines/COX-2/iNOS modulation
  2. Growth/survival signaling downshift (PI3K–Akt–mTOR and intersecting MAPK nodes; context- and model-dependent)
  3. Redox modulation (biphasic): antioxidant tone and inflammatory redox dampening at low exposure; pro-oxidant stress signaling at high concentration in tumor models (secondary)
  4. Mitochondria-linked intrinsic apoptosis and cell-cycle checkpoint control (often downstream of NF-κB/Akt/redox)
  5. Anti-invasive/anti-metastatic remodeling (EMT programs, MMPs, adhesion/invasion)
  6. Anti-angiogenic signaling (VEGF axis; endothelial migration/tube formation)
  7. Metabolic reprogramming pressure (HIF-1α/glycolysis programs; secondary, model-dependent)
  8. Microbiome–host signaling (barrier function, metabolite signaling, bile acid/SCFA context; indirect systemic mechanism)
  9. NRF2 antioxidant response activation in normal tissues with mixed implications in NRF2-addicted tumors (secondary)

Bioavailability / PK relevance: Oral bioavailability of intact parent anthocyanins is generally modest with rapid appearance and clearance; extensive phase-II metabolism (glucuronidation/sulfation/methylation) and prominent gut microbiota catabolism generate phenolic acid metabolites that may dominate systemic exposure. Local gastrointestinal exposures can be substantially higher than plasma levels, making “GI-local” mechanisms more plausible than “systemic parent-compound” mechanisms for many endpoints.

In-vitro vs systemic exposure relevance: Many anticancer in-vitro studies use ~10–100+ µM parent anthocyanins/extract equivalents, which often exceed achievable circulating parent anthocyanin concentrations after dietary intake; therefore, mechanistic claims that require high micromolar parent exposure should be treated as (high concentration only) unless supported by metabolite biology or GI-local relevance.

Clinical evidence status: Human evidence is strongest for cardiometabolic and inflammation-related biomarkers (multiple RCTs/meta-analyses). For cancer, evidence is predominantly preclinical and epidemiologic/biomarker-level in humans; there is no established oncology indication or regulatory approval as an anticancer drug. For cognition/brain aging, small RCTs with anthocyanin-rich foods/supplements show signal in select domains, but overall evidence remains exploratory.

"Anthocyanins are a class of water‐soluble flavonoids, which show a range of pharmacological effects, such as prevention of cardiovascular disease, obesity control and antitumour activity. Their potential antitumour effects are reported to be based on a wide variety of biological activities including antioxidant; anti‐inflammation; anti‐mutagenesis; induction of differentiation; inhibiting proliferation by modulating signal transduction pathways, inducing cell cycle arrest and stimulating apoptosis or autophagy of cancer cells; anti‐invasion; anti‐metastasis; reversing drug resistance of cancer cells and increasing their sensitivity to chemotherapy."
Anthocyanins are flavonoid pigments with multi-target pleiotropic effects in cancer models, primarily through modulation of ROS balance, NF-κB signaling, PI3K/Akt/mTOR inhibition, apoptosis induction, and anti-angiogenic activity. Their effects are often context-dependent and dose-dependent: low physiologic exposures tend to support antioxidant and anti-inflammatory tone, whereas higher concentrations in vitro can induce oxidative stress and apoptosis in tumor cells. They also influence tumor microenvironment dynamics including VEGF signaling, MMP activity, and inflammatory cytokines. Bioavailability is modest, and metabolites (phenolic acids) likely contribute significantly to biological effects. Evidence in humans remains supportive but not definitive.
• Anthocyanins are a class of water-soluble flavonoid pigments responsible for the red, purple, and blue hues in many fruits, vegetables, and flowers (e.g., berries, red grapes, and eggplants).
• Anthocyanins can effectively scavenge free radicals and reduce oxidative stress, thereby protecting cellular components like DNA, lipids, and proteins from oxidative damage—a factor linked to carcinogenesis.
• Their antioxidant capacity helps in neutralizing reactive oxygen species (ROS), which can otherwise promote mutations and tumor initiation.
• Anthocyanins have been shown to inhibit pro-inflammatory cytokines (e.g., TNF-α, IL-6) and enzymes (e.g., COX-2), reducing the inflammatory signals associated with cancer progression.
• They may modulate pathways such as NF-κB, MAPK, and PI3K/Akt, contributing to the downregulation of genes involved in survival and proliferation of cancer cells.
• Anthocyanins have been found to inhibit the formation of new blood vessels (angiogenesis) essential for tumor growth and metastatic spread.

Anthocyanins: ranked cancer-relevant pathway effects

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 NF-κB inflammatory transcription NF-κB ↓; IL-6/TNF-α/COX-2/iNOS ↓ (model-dependent) Inflammatory tone ↓; endothelial/immune activation ↓ (context-dependent) R, G Anti-inflammatory, anti-survival signaling pressure Often the most reproducible “systems-level” effect across anthocyanin mixtures; frequently upstream of apoptosis, invasion, and angiogenesis programs.
2 PI3K–Akt–mTOR growth and survival Akt ↓; mTOR ↓; survival signaling ↓ (model-dependent) Metabolic stress signaling ↔/↓ (context-dependent) R, G Anti-proliferative signaling shift Commonly reported in breast/colon/liver/prostate models; “extract” studies can reflect multi-node inhibition rather than a single target.
3 Mitochondria and intrinsic apoptosis MOMP ↑; caspases ↑; Bcl-2 family shift toward apoptosis (model-dependent) Pro-apoptotic signaling ↔/↓ at nutritional exposure; stress resistance ↑ (context-dependent) R, G Apoptosis induction / survival loss Frequently downstream of redox or Akt/NF-κB suppression; strong in vitro, but dose-exposure realism is the key constraint.
4 ROS balance ROS ↑ (high concentration only) or ROS ↓ (context-dependent) ROS ↓; lipid peroxidation markers ↓ (often) P, R Redox buffering or stress signaling Biphasic: antioxidant/anti-inflammatory at low exposure; pro-oxidant stress signaling at higher concentrations in tumor models is reported but may be exposure-limited systemically.
5 EMT and invasion programs EMT ↓; migration/invasion ↓ (model-dependent) Tissue remodeling ↔ (context-dependent) G Anti-invasive phenotype pressure Often linked to NF-κB, TGF-β/Smad, and MMP suppression; more consistent for “behavioral endpoints” than for a single molecular node.
6 MMPs and extracellular matrix degradation MMP-2 ↓; MMP-9 ↓ (model-dependent) ECM turnover ↔ (context-dependent) G Reduced metastatic potential Pairs mechanistically with EMT suppression and inflammatory signaling downshift.
7 Angiogenesis and VEGF axis VEGF signaling ↓; endothelial support ↓ (model-dependent) Endothelial activation ↓ (context-dependent) G Anti-angiogenic pressure Typically secondary to NF-κB/HIF-1α modulation; most convincing in models rather than as a clinically validated endpoint.
8 Cell-cycle checkpoints G1/S or G2/M arrest ↑ (model-dependent) Cell-cycle stress ↔/↓ (context-dependent) R, G Proliferation restraint Often emerges as an integrated phenotype downstream of Akt/NF-κB redox signaling rather than a direct CDK inhibitor effect.
9 HIF-1α and glycolysis programs HIF-1α ↓; glycolysis gene program ↓ (model-dependent) Metabolic flexibility ↔ (context-dependent) G Metabolic reprogramming pressure Best treated as secondary unless a specific anthocyanin/metabolite mechanism is shown at realistic exposure.
10 NRF2 antioxidant response NRF2 ↔/↑/↓ (model-dependent) NRF2 ↑; cytoprotective enzymes ↑ (often) R, G Stress-response adaptation Potential benefit in normal-tissue protection; theoretical caution if a tumor is NRF2-addicted or relies on high antioxidant capacity.
11 Ca²⁺ signaling Ca²⁺ flux ↔/disrupted (model-dependent) Excitotoxic stress signaling ↓ (context-dependent) P, R Signal modulation under stress Reported in subsets of models; generally not treated as a primary axis unless tied to a clear phenotype (e.g., apoptosis, barrier function).
12 Clinical Translation Constraint Systemic parent exposure often low; heterogeneity of mixtures; biomarker-to-outcome gap Generally favorable food safety profile Limits on “drug-like” claims Interpretation should weight GI-local effects, metabolite biology, and RCT biomarker outcomes higher than high-µM in-vitro parent-compound findings.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr



Anthocyanins and Alzheimer’s disease — Anthocyanin-rich foods/supplements have small-human-trial signals suggesting modest improvements in selected cognitive domains and/or brain function proxies in at-risk or impaired cohorts, plausibly mediated through vascular/inflammatory tone, oxidative stress buffering, and microbiome–metabolite signaling (rather than sustained high circulating parent anthocyanins). Overall, evidence remains exploratory and heterogeneous across preparations, doses, and endpoints.

Clinical evidence status: Small RCTs/pilot trials (food-based and some purified preparations) with mixed but promising signals; not an established disease-modifying therapy.

Anthocyanins: non-cancer mechanisms relevant to Alzheimer’s disease

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 Neuroinflammation Lower inflammatory signaling tone Human biomarker/meta-analytic evidence supports anti-inflammatory effects in non-cancer contexts; translation to dementia outcomes remains unproven.
2 Oxidative stress and redox homeostasis Reduced oxidative burden; cytoprotection Mechanistically consistent with polyphenol biology; likely mediated substantially by metabolites rather than sustained parent anthocyanins.
3 Neurovascular and endothelial function Support for perfusion/vascular tone Common mechanistic bridge between cardiometabolic benefits and brain aging hypotheses; endpoints vary by trial design.
4 Gut microbiota–metabolite axis Metabolite signaling, barrier support Growing evidence that gut-derived phenolic acids contribute to systemic and possibly neuroactive effects; causal mapping in humans is still developing.
5 Aβ processing and proteostasis Potential reduction in amyloidogenic pressure Preclinical and mechanistic papers exist; human evidence for amyloid/tau modification is limited and not definitive.
6 Clinical Translation Constraint Heterogeneous preparations and endpoints Signals exist in small RCTs/pilots, but dose standardization, metabolite exposure mapping, and durable clinical outcomes remain the key gaps.


BioEnh, bioenhancer: Click to Expand ⟱
Source:
Type:
A bioenhancer is an agent capable of enhancing bioavailability and efficacy of a drug with which it is co-administered

Query Database for BioEnhancers but the bioenhancers mainly show up under the target notes

Bioenhancers
- piperine and quercetin are considered bio-enhancers
- genistein
Piperine act by suppressing P-gp and cytochrome P450 enzymes, which counteract the metabolism of rifampicin via these proteins, thus enhancing the oral bioavailability of rifampicin. It also decreases the intestinal production of glucuronic acid, thus allowing more substances to enter the body in active form. It was found to increase the bioavailability of various drugs from 30% to 200%.[25]
Table 1: Published research on bioenhancer effect of piperine with various medicines
Drug Studied in Reference
Antimicrobial agents
Rifampicin In vitro Balakrishnan et al, 2001[11]
Isoniazid Rabbits Karan et al, 1998 [12]
Pefl oxacin Mountain Gaddi goats Madhukar et al, 2008[13]
Tetracycline Rats Atal et al, 1980[14]
Sulfadiazine Rats and dogs Atal et al, 1980[14]
Oxytetracycline Poultry birds Singh et al, 2005[15]
Ampicillin Rabbits Janakiraman and Manavalan, 2008[16]
Norfl oxacin Rabbits Janakiraman and Manavalan, 2008 [16]
Nevirapine Adult males Kasibhatta et al, 2007 [17]
Metronidazole In vitro Singh et al, 2010[18]
Analgesics
Diclofenac sodium Albino mice Pooja et al, 2007[19]
Pentazocine Albino mice Pooja et al, 2007[19]
Nimesulide Mice Gupta et al, 1998[20]
Antiepileptics
Carbamazepine In vitro Pattanaik et al, 2009 [21]
Phenytoin Human volunteers Bano et al, 1987[22]
Pentobarbitone Rats Majumdar et al, 1990[23]
Other drugs
Propranolol In vitro Bano et al, 1991 [24]
Theophylline In vitro Bano et al, 1991 [24]
Nutrients In vitro Pooja et al, 2007 [19
***Borneol
-Borneol is thought to temporarily open tight junctions between endothelial cells, enhancing drug penetration. It may also downregulate efflux transporters such as P-glycoprotein (P-gp), allowing higher intracellular concentrations of co-administered drugs.

-presence of urea (as a carrier) increased the aqueous solubility of capsaicin by 3.6-fold compared to pure capsaicin

Quercetin is found in citrus fruits and is a dual inhibitor of cytochrome P 3A4 (CYP3A4) and P-gp.
Table 2: Effect of quercetin pretreatment/co-treatment on pharmacokinetic parameters of different drugs
Drugs combined Increase in pharmacokinetic parametera
Cmax AUC ABA
Verapamil Two fold Two fold SH
Diltiazem SH SH Not known
Paclitaxel SH SH T wo fold
Digoxin 413% 170% Not known
Tamoxifen SH SH 59%
Compared to drug in question alone. Cmax, peak plasma concentration; AUC, area under the curve; ABA, absolute bioavailability; SH, significantly higher.

Another flavonoid, genistein belongs to the isoflavone class of flavonoids. It is a well-known phytoestrogen. The presence of genistein (10 mg/kg) caused an increase in AUC (54.7%) and a decrease in the total plasma clearance (35.2%) after oral administration of paclitaxel at a dose of 30 mg/kg in rats.[37]
Naringin is the major flavonoid glycoside found in grapefruit and makes grapefruit juice taste bitter. Oral naringin (3.3 and 10 mg/kg) was pretreated 30 min before and after intravenous administration of paclitaxel (3 mg/kg), the AUC was significantly improved (40.8% and 49.1% for naringin doses of 3.3 and 10 mg/kg, respectively).[38

Carum carvi/Cuminum cyminum ( Jeera)
Carum carvi seeds are a prized culinary herb. Extracts of its parts increased significantly (25%–300%), the bioavailability of a number of classes of drugs, such as antibiotics, antifungals, antivirals, anticancer, cardiovascular, anti-inflammatory/ antiarthritic, anti-TB, antileprosy, antihistaminic/respiratory disorders, corticosteroids, immunosuppressants, and antiulcers. Such extracts either in the presence or absence of piperine have been found to be highly selective in their bioavailability/bioefficacy-enhancing action.[40]
Capmul
One of the widely used bioenhancers is Capmul MCM C10, a glyceryl monocaprate, produced from edible fats and oils and is commonly used in lip products. In a study in rats, antibiotic ceftriaxone when given concomitantly with capmul, increased the bioavailability of ceftriaxone by 80%.[41]
Nitrile glycoside
Nitrite glycoside is a bioenhancer for drugs and nutrients. Novel bioactive nitrile glycosides, niaziridin and niazirin is obtained from the leaves, pods, and bark of Moringa oleifera. [42] An immunoenhancing polysaccharide and niaziminin, having structural requirement to inhibit tumor promoter-induced Epstein–Barr virus activation have been reported from the leaves of Moringa.[43,44] It enhances the bioactivity of commonly used antibiotics, such as rifampicin, tetracycline, and ampicillin, and also facilitate the absorption of drugs, vitamins, and nutrients through the gastrointestinal membrane, thus increasing their bioavailability. [41] Niazirin is another bioactive nitrile glycoside belonging to M. oleifera. [45,46] Process of isolation of nitrite glycoside from M. oleifera has been patented (US 6858588) by Khanuja et al in 2004–2005. [42

Mechanism of Action Of Bioenhancers
Bioavailability-enhancing activity of natural compounds from the medicinal plants may be attributed to various mechanisms, such as P-gp inhibition activity by flavone, quercetin, and genistein; [51] inhibition of efflux transporters, such as P-gp and breast cancer resistance protein (BCRP),[52,53] by naringin and sinomenine thus preventing drug resistance; DNA receptor binding, modulation of cell signaling transduction, and inhibition of drug efflux pumps[54-56] ; by stimulating leucine amino peptidase and glycyl–glycine dipeptidase activity, thus modulating the cell membrane dynamics related to passive transport mechanism as seen with piperine [57] ; nonspecific mechanisms, such as increased blood supply to the gastrointestinal tract, decreased hydrochloric acid secretion, preventing breakdown of some drugs[6] ; and inhibition of metabolic enzymes participating in the biotransformation of drugs, thus preventing inactivation and elimination of drugs and thereby, increasing their bioavailability. [57-5]


Scientific Papers found: Click to Expand⟱
7714- IP6,  ACNs,    Enhanced absorption of anthocyanins after oral administration of phytic acid in rats and humans
- in-vivo, Nor, NA
*BioEnh↑, *BioAv↑, *Dose↝,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Drug Metabolism & Resistance(tgid=21)

BioAv↑, 1,   BioEnh↑, 1,   Dose↝, 1,  
Total Targets: 3

Scientific Paper Hit Count for: BioEnh, bioenhancer
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:31  Target#:1310  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page